GSK to implement Medidata Designer for its Clinical Research and Development organization

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical technology solutions, today announced that GlaxoSmithKline (GSK) has decided to implement Medidata Designer^®, an innovative study design optimization solution, for its Clinical Research and Development organization. Using Designer, GSK can consistently design studies that meet key objectives and collect necessary data in a streamlined and efficient manner.

"Medidata Designer is unique in its ability to help sponsors more efficiently manage the process of study design, as well as bring efficiency to the actual design of their studies and downstream study execution," said Glen de Vries, president, Medidata Solutions. "Using Designer's cost and complexity benchmarking, along with its easy-to-use interface and protocol quality controls, GSK can eliminate unnecessary procedures and focus its efforts on the most important study objectives."

Medidata Designer drives study design quality with a CDISC-compliant data model that enforces the links across objectives, end points and procedures. This reusable metadata accelerates system setup, such as electronic data capture build, and automates the derivation of protocols and other key clinical deliverables. It improves compliance with standards, allows clinicians to focus on the science of clinical research and not on document management, and speeds study starts, shortening time to market for new therapies.